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Objective: This review summarizes published findings concerning the Baerveldt-350 glau-
coma drainage device (GDD). Most studies focus on the comparison between different 
treatments; in this review, the primary focus is efficacy, safety, and place in therapy for the 
Baerveldt implant.
Methods: A systematic review was performed using the PubMed database for literature on 
March 13th, 2020. Efficacy was estimated by performing multiple meta-analyses to calculate 
the weighted mean difference in intraocular pressure (IOP) and IOP-lowering medication 
after surgery. In order to get an indication of the safety of the Baerveldt implant, all recorded 
peri- and postoperative complication were summarized.
Results: A total of 21 studies, including 12 randomized controlled trials, were included with 
a follow-up up to 5 years, covering a mix of glaucoma types. At the last follow-up point, at 5 
years postoperative, the mean (95% confidence interval) reduction in IOP was 15.57 mmHg 
(14.43–16.71) and the mean (95% confidence interval) reduction in IOP-lowering medication 
after surgery was 1.81 (1.61–2.01). Most frequently observed postoperative complications 
were corneal edema (2–34%) and tube complications (4–33%). Rates of required re-inter-
vention ranged from 0% to 51% across all included studies.
Conclusion: The efficacy of the Baerveldt implant is a significant reduction in IOP in the 
long term. The safety profile of the Baerveldt implant in terms of complication incidence is 
similar to those reported for other GDD's. For treatment of secondary glaucoma, we suggest 
the Baerveldt (or any other similar GDD) as the choice of treatment in patients where highest 
IOP reduction is desired.
Keywords: Baerveldt implant, glaucoma drainage device, glaucoma, intraocular pressure
Introduction
Glaucoma is a neurodegenerative eye disease for which only one modifiable risk 
factor has been identified till date: (increased) intraocular pressure (IOP). For 
several decades glaucoma belongs to the most common causes of irreversible 
blindness worldwide. Although normal-tension glaucoma exists, usually the IOP 
is increased above 21mmHg which causes optic nerve strain. Rapid increase or 
continuous high IOP leads to damage of the optic nerve, causing irreversible visual 
field loss.1
Glaucoma can be caused by various factors. Primary open angle glaucoma is the 
most common form of glaucoma and is caused by obstruction of the trabecular 
meshwork. Less frequent, glaucoma can also primarily be caused by closure of the 
anterior chamber angle or secondary, by e.g. uveitis, pigment dispersion, or exfolia-
tion. In any case, treatment of glaucoma is always oriented around decreasing the 
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IOP, which can be achieved by medical treatment, laser 
treatment, or surgery.2 The first step often consists of 
topical medication, resulting in decreased production and/ 
or increased outflow of aqueous humor. Alternatively, 
laser treatment can be used in various ways, either to 
decrease production of aqueous humour, or to increase 
aqueous outflow.3 Finally, surgical intervention is avail-
able as another viable treatment option. Two commonly 
used surgical methods are trabeculectomy and the implan-
tation of a glaucoma drainage device (GDD) such as the 
Baerveldt implant.
In February 1990, the Baerveldt implant was intro-
duced in California (USA) and is used worldwide ever 
since. The Baerveldt-350 consists of a non-valved silicone 
tube (0.63 mm external diameter, 0.30 mm inner dia-
meter). It is attached to a medical-grade silicon plate 
with a large surface area of 350mm2, which is placed 
with its ends beneath the recti muscles, commonly in the 
superotemporal quadrant.4
This review summarizes published findings from ran-
domized controlled trials (RCT) and non-randomized stu-
dies concerning the Baerveldt implant. Most studies 
focused on the comparison between different treatments. 
In this review the primary focus is efficacy, safety, and 
place in therapy for the Baerveldt implant.
Methods
Data Search and Study Selection
A systematic review was performed using the guidelines 
implied by the Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA; Liberati et al 
2009). The PubMed database was searched for studies 
describing the Baerveldt implant published until March 
13th, 2020. The following MeSH terms were used: (baer-
veldt[All Fields] AND implant[All Fields]) OR (baerveldt 
[All Fields] AND glaucoma[All Fields]) OR (baerveldt 
[All Fields] AND device[All Fields]). The search query 
was limited to include the following article types: clinical 
study, clinical trial, comparative study, meta-analysis, 
observational study, RCT, review, and systematic reviews. 
All eligible articles had to have an available abstract in 
English language, had to be performed in humans or on 
human tissue, and had to be peer-reviewed. From the 
retrieved studies, titles and abstracts were scanned. Next, 
the full-text was read and the reference lists from all 
identified studies were scanned in the same way to find 
other allegeable studies.
Data Extraction and Quality Assessment
All retrieved studies had to report on either postoperative 
IOP, postoperative IOP-lowering medication or peri/post-
operative complications. The peri/postoperative complica-
tions had to be listed with a percentage indicating the 
incidence during follow-up for the Baerveldt implant. 
Also, only complications reported by studies from the 
last 20 years were included, because of technical improve-
ments last decades. Identical or very similar complications 
were grouped. Complications were categorized as “perio-
perative”, “early postoperative” (≤3 months), and “cumu-
lative postoperative” (≤5 years).
Quality of the included articles was assessed based on 
the dictated level of evidence according to Levels of 
Evidence For Primary Research Question, adopted by the 
North American Spine Society. Finally, for the postopera-
tive IOP and postoperative IOP-lowering medication ana-
lysis, only high level of evidence randomized controlled 
trials were selected. For the complication assessment, RCT 
and non-RCT studies were analyzed separately.
Data Analysis
Not all articles reported data at every follow-up moment. 
For each time interval, the mean from all included studies 
was calculated in regard to the included eye at that time 
interval. Next, the mean and standard deviation were used 
in the meta-analysis to calculate the weighted mean differ-
ences (WMDs) with their corresponding 95% confidence 
interval (CI) for each time interval. Heterogeneity was 
evaluated by calculating theI2-statistics.
Using this method, the WMD of postoperative IOP 
across the retrieved studies was calculated for the 
Baerveldt implant at 1 day, 1 week, 1 month, 6 months, 
1 year, 35 years of follow-up. This method was also used 
to analyze the change in number of IOP-lowering medica-
tions. Data analysis was performed using RevMan 5 for 
Windows (The Cochrane Collaboration, Oxford, UK) and 
Microsoft Excel for Windows (Microsoft, Redmond, 
Washington, US).
Results
The initial literature search on Pubmed resulted in a total 
of 402 articles. After applying search limits and additional 
filters, 88 articles remained. After reading the full text for 
inclusion criteria, a total of 21 studies, including 12 ran-
domized controlled trials were included.5–25 (Figure 1). 
All RCT studies had a follow-up ranging from 1 to 5 
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Figure 1 Flowchart of Pubmed search. 
Abbreviation: RCT, randomized controlled trial
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years, covered a mix of glaucoma types and compared the 
superotemporal placed, perioperatively occluded Baerveldt 
350mm implant to other interventions (Table S1).
Multiple RCT articles resulted from the three large 
Baerveldt studies: the ‘Tube Versus Trabeculectomy 
Study’, the ‘Ahmed Versus Baerveldt Study’ and the 
‘Ahmed Baerveldt comparison study’. Other (non-RCT) 
studies had a follow-up ranging from 0.5 to 5 years, 
covered a mix of glaucoma types and generally compared 
the superotemporal placed, perioperatively occluded 
Baerveldt 350mm (or 250mm) implant to other 
interventions.
Postoperative IOP Reduction
Of the included studies, 8 articles presented the postopera-
tive IOP reduction in mmHg with standard deviation or 
95% CI interval (Figure 2). At 1 day postoperative, the 
IOP reduction (WMD 95% CI) was 6.90 mmHg (5.65– 
8.15), which remained stable till 1 month. Thereafter the 
IOP reduction increased strongly to 11.42 mmHg (10.64– 
12.19) at 6 months postoperative. The reduction in IOP 
then became somewhat less but kept increasing the follow-
ing years. At 1 and 3 years postoperative both the IOP 
reduction (WMD 95% CI) were 12.66 mmHg (11.93– 
13.39) and 12.69 mmHg (11.91–13.47), respectively. At 
the last follow-up point, at 5 years postoperative, the 
WMD (95% CI) reduction in IOP was 15.57 mmHg 
(14.43–16.71; Figure 3).
Postoperative IOP-Lowering Medication 
Reduction
A reduction in postoperative IOP-lowering medication was 
presented by 7 of the included studies (Figure 4). At 1 day 
postoperative, the reduction in number of IOP-lowering 
medication (WMD [95% CI]) was 1.90 (1.53–2.27), how-
ever, only one study reported this. At 1 week postopera-
tive, the medication reduction increased to 2.09 (1.92– 
2.25). From 1 month postoperative till the last follow-up 
point, at 5 years postoperative, the WMD (95% CI) reduc-
tion of IOP-lowering medication remained stable 1.86 
(1.69–2.03) and 1.81 (1.61–2.01; Figure 3), respectively.
Perioperative and Postoperative 
Complications
The peri- and postoperative complications from RCT and 
non-RCT studies were listed with their corresponding 
ranges of incidence (Table S2). Perioperative 
complications were reported by two of the RCT studies. 
Hyphema (1–3%) and scleral perforation (3%) were the 
most frequently recorded perioperative complications. 
Early postoperative complications were reported by two 
RCT and three non-RCT studies for the first 3 months 
postoperative.
For the postoperative complications, corneal edema 
had the highest incidence range. In 12–34% of all recorded 
patients this complication occurred with according to one 
article, 22% occurring in the first 3 months. Tube compli-
cations had the next highest incidence range of up to 33% 
(16% in the first 3 months). Tube complications consisted 
mainly out of (unintended) tube occlusion, tube erosion, 
and tube malposition. Other complications that were fre-
quently recorded were hyphema (2–19%), diplopia or 
motility disorders (2–17%). Cataract progression was 
excluded by most articles from their complication analysis, 
two studies however reported cataract progression in 41% 
of their operated patients. In total, the rates of required re- 
intervention ranged from 22–51% across all analyzed RCT 
studies.
The incidence of more severe complications was nota-
bly less with endophthalmitis or blebitis at 1–2%, retinal 
detachment at 1–2% and phthisis bulbi at 2–6% of all 
eyes. In 6% of all operated eyes (a progression to) no 
light perception occurred.
For the additional nine (non-RCT) studies, incidence 
ranges are relatively similar although somewhat higher. 
Notable exceptions are diplopia/motility disorder and cor-
neal edema, which are recorded less frequently at only 
4–9% and 2–19% respectively. Also tube complications 
(4–13%) and cataract progression (4–6%) were reported 
less in the non-RCT studies. In total, re-intervention was 
required at 0–19% of all performed Baerveldt implanta-
tions reported in the additional non-RCT studies.
Discussion
This review summarizes published findings concerning the 
Baerveldt-350 GDD. At the last follow-up point, at 5 years 
postoperative, the mean (95% CI) reduction in IOP was 
15.57 mmHg (14.43–16.71) and the mean (95% CI) reduc-
tion in IOP-lowering medication after surgery was 1.81 
(1.61–2.01). Most frequently observed postoperative com-
plications were corneal edema (2–34%) and tube compli-
cations (4–33%), both early and late/persisting in follow- 
up. In 0–51% of all recorded follow-up patients re-inter-
vention was required.
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Figure 2 Calculated means for reduction IOP at 1 day (2.A), 1 week (2.B), 1 month (2.C), 6 months (2.D), 1 year (2.E), 3 years (2.F) and 5 years (2.G) follow-up. 
Notes: Black diamonds indicate the overall weighted mean difference (WMD). The size of the green box is inversely proportional to the variance. Horizontal lines indicate 
95% confidence interval (CI). The solid vertical line in each panel shows the value for no difference (WMD = 0). 
Abbreviation: IOP, intraocular pressure.
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Efficacy
At one month after surgery, the Baerveldt implant showed 
a relatively small IOP reduction of 7.0 mmHg. After 
approximately 6–8 weeks the suture tied around the tube 
resolves and the flow through the tube starts, resulting in a 
higher decrease in IOP. At 6 months after surgery the IOP 
reduction greatly improves, with a final reduction of 
15.57 mmHg from baseline at 5 years follow-up. For the 
RCT articles, this corresponds with an IOP reduction from 
baseline between 41–55% at 5 years follow-up. However, 
the increased IOP reduction at 5 years follow-up 
(Figure 3) is likely caused by currently unavailable 5 
year data from the Primary Tube Versus Trabeculectomy 
study.5,6 According to Gedde et al,26 the Primary Tube 
Versus Trabeculectomy study has a lower baseline IOP 
resulting in lower IOP reduction, causing a lower mean 
IOP reduction on other follow-up points in the meta-ana-
lysis (Figure 2).
The reduction in IOP-lowering medication fluctuates 
during the first month, but remains relatively constant with 
a mean reduction of 1.81 IOP-lowering medication from 
baseline at 5 years of follow-up.
When compared to other common treatment options, 
results were similar. In the Ahmed Baerveldt Comparison 
study, it is reported that for the first month the Ahmed FP7 
delivered a greater reduction in IOP and IOP-lowering 
medication, but the Baerveldt achieved a greater decrease 
afterwards.13,14 At 5 years of follow-up they report an 
approximately 2 mmHg-lower IOP for the Baerveldt 
group. In the Ahmed Versus Baerveldt study by 
Christakis et al,11,12 slightly better IOP and medication 
reduction were reported for the Baerveldt group. When 
compared to trabeculectomy in the Tube versus trabecu-
lectomy study,7,10 they reported a difference in IOP reduc-
tion of approximately 2 mmHg in favor of trabeculectomy.
In the long term, the IOP-lowering potential of the 
Baerveldt implant is even somewhat better than that of the 
other frequently used Ahmed FP7, which might be 
explained by the fact that the implant endplate of the 
Baerveldt implant is bigger than that of the Ahmed implant. 
Studies between different Baerveldt sizes and between 
Molteno implant variations show that higher success rates 
and greater long-term IOP control are found when devices 
with larger endplates are implanted.16,27,28 Another possible 
explanation could be that with the Baerveldt implant, the 
initially tied tube results in less exposure of the bleb to 
inflammatory cells, cytokines, and proteins post-surgery, 
resulting in less scarring of the fibrous capsule surrounding 
the end plate when compared to the Ahmed implant.27
Safety
Overall, relatively high rates with wide ranges of post-
operative complications were reported.
However, when looking at other common treatment 
options, complications are often reported at similar or 
just slightly lower incidences. The Ahmed versus 
Baerveldt study reported a slightly lower complication 
rate for the Ahmed FP7 but an identical percentage of 
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Figure 3 Mean reduction in postoperative IOP (mmHg; solid line) and number of IOP-lowering medications (dashed line). 
Notes: Dots represent mean. Bars represent 95% confidence interval. 
Abbreviation: IOP, intraocular pressure.
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Figure 4 Calculated means for IOP-lowering medication reduction at 1 day (4.A), 1 week (4.B), 1 month (4.C), 6 months (4.D), 1 year (4.E), 3 years (4.F) and 5 years (4.G) 
follow-up. 
Notes: Black diamonds indicate the overall weighted mean difference (WMD). The size of the green box is inversely proportional to the variance. Horizontal lines indicate 
95% confidence interval (CI). The solid vertical line in each panel shows the value for no difference (WMD = 0). 
Abbreviation: IOP, intraocular pressure.
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postoperative interventions.12 A larger number of compli-
cations attributed to an early onset hypotony were seen in 
the Baerveldt group, likely due to the absence of a built-in 
flow restriction. In the Ahmed Baerveldt Comparison 
study, a higher percentage of serious complications leading 
to postoperative surgical interventions was reported in the 
Bearveldt group. Surgical re-intervention was required 5% 
more with the Baerveldt implant than with the Ahmed 
implant, mainly due to hypotony (related) difficulties.15 
Other frequent complications however, such as corneal 
edema and diplopia, were seen just as often in both groups. 
When compared to trabeculectomy in the Tube versus 
trabeculectomy study, they report a large number of com-
plications for both interventions albeit mostly transient and 
self-limiting.10 Early postoperative complications were 
reported 16% more frequent following trabeculectomy 
than in the Baerveldt group. Wound leak in particular 
was more common after trabeculectomy resulting from 
the immediate filtration. Because of the smaller surgical 
opening and the fact that this opening is commonly cov-
ered by a patch (donor sclera or other tissue), the incidence 
of wound leakage is much lower. At 5 year follow-up 
however, further complications, re-interventions and sec-
ondary cataract progression were similar for both groups.
Place in Therapy
Of all commonly used GDD’s the IOP-lowering effect of 
the Ahmed FP7 has the fastest effect in the short term 
(similar to trabeculectomy).7,8,13,14 The Ahmed FP7 
decreases IOP to a greater degree in the early postopera-
tive period compared to the Baerveldt-350.29 Nevertheless, 
in the long term the Baerveldt-350 had a greater IOP- 
reduction and a similar incidence of glaucoma reopera-
tions than the Ahmed FP7 after 5 years of follow-up.-
12,14,15 According to the Tube versus trabeculectomy 
study, the trabeculectomy resulted in a statistically signifi-
cant lower IOP than Baerveldt-350.8,10 Whether this dif-
ference of 2 mmHg is clinically significant remains 
debatable. Therefore, according to current scientific evi-
dence, the trabeculectomy might be in favor as surgical 
therapy of primary open-angle glaucoma. However, for 
secondary causes of glaucoma (e.g. uveitic or traumatic 
glaucoma) the fibrosis or scarring can be challenging. Also 
trabeculectomy can be more demanding in terms of fol-
low-up appointments, especially in the early postoperative 
period. More checkups are required due to e.g. risk of 
wound leakage, over- or underfiltration or removal of 
sutures, resulting in more load on both doctor and patient 
when compared to the GDD’s with a somewhat more 
predictable postoperative course. Moreover, as the differ-
ence in efficacy between the Baerveldt-350 and the trabe-
culectomy is very low and the safety of the Baerveldt-350 
might be better in terms of fibrosis due to e.g. uveitis, the 
Baerveldt (or any other GDD) would be in favor in these 
cases.29 Unfortunately, RCT studies on trabeculectomy vs 
Ahmed FP7 are lacking, making it hard to choose a spe-
cific GDD.
Conclusion
In conclusion, the Baerveldt-350 glaucoma implant device 
has been available for a relatively long time. It is effective 
in lowering IOP and has the highest long-term IOP-low-
ering potential of all assessed GDD’s. Furthermore, its 
complication incidence seems similar to other GDD’s 
and shows all-round good performance. For treatment of 
secondary open-angle glaucoma tube implants are first 
choice, stated characteristics make the Baerveldt implant 
the GDD of choice in patients where the highest IOP 
reduction is desired. However, the relatively small number 
of randomized controlled trials still results in the desire for 
more trials. Moreover, the high rates of complications 
warrant comparisons to newer minimally invasive glau-
coma implants.
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